(Reuters) -BioAge Labs is eyeing a valuation of up to $639.7 million in its upsized initial public offering in the United ...

BioAge Labs is eyeing around $180 million in initial proceeds from an IPO and a private placement, funds the ...

While several factors predict sustained glycemic control, predictors of sustained weight control with tirzepatide appear ...

In particular, semiconductor specialist Nvidia is viewed as the engine powering the AI vehicle right now. Demand for its most ...

Minnesota clinics are starting to receive free or low-cost insulin from Eli Lilly and Sanofi. This comes after the Minnesota ...

Novo Nordisk and Eli Lilly are expected to rule the obesity market for a few more years without much challenge. To ensure they stay there as competition enters, the companies are spending billions in ...

Amgen said on Tuesday that its drug helped improve daily activities including chewing and swallowing in patients suffering ...

Weight-loss drugs sell in Europe for a fraction of what they cost in the United States, a pattern that is typical for ...

China has started cracking down on unlicensed production and sale of medicines similar to Novo Nordisk A/S’s blockbuster ...

U.S. Senator Bernie Sanders said on Tuesday he had commitments from the nation's top pharmacy benefit managers that they ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 594.50% and ...

Japan, with its rapidly aging population, is expected to have more than 5 million patients with dementia by 2030. Alzheimer’s ...